|
2008
|
Invention
|
Use of glp-1 as a therapeutic agent.
The present invention is directed to the use of the peptide... |
|
|
Invention
|
Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent.
The presen... |
|
|
Invention
|
Use of a peptide as a therapeutic agent.
The present invention is directed to the use of the pep... |
|
|
Invention
|
Use of salusin beta alone or in combination with octreotide as a therapeutic agent.
The present ... |
|
|
Invention
|
Use of a peptide as a therapeutic agent.
The present invention is directed to the use of the com... |
|
|
Invention
|
Use of cnp-22, alone or in combination with physalemin, as a therapeutic agent.
The present inve... |
|
|
Invention
|
Use of fibronectin fragment (196-203 ) as a therapeutic agent.
The present invention is directed... |
|
|
Invention
|
Use of the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys as a therapeutic a... |
|
|
Invention
|
Use of the peptide asn-asp-asp-cys-glu- leu-cys-val-asn-val-ala-cys-thr-gly-cys-leu alone or in c... |
|
|
Invention
|
Use of il-1 receptor peptide, alone or in combination with d-ala-gln-octadecyl ester, as a therap... |
|
|
Invention
|
Use of rfrp, alone or in combination with neurokinin-b, as a therapeutic agent.
The present inve... |
|
|
Invention
|
Use of urocortin and corticotropin-releasing factor as therapeutic agents.
The present invention... |
|
|
Invention
|
Use of a tuftsin as a therapeutic agent.
The present invention is directed to the use of the pep... |
|
|
Invention
|
Minigastrin as a therapeutic agent.
The present invention is directed to the use of the peptide ... |
|
|
Invention
|
Trap-14 as a therapeutic agent.
The present invention is directed to the use of the peptide comp... |
|
|
Invention
|
Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic ... |
|
|
Invention
|
Thyrotropin releasing hormone for therapeutic applications.
The present invention is directed to... |
|
|
Invention
|
Use of peptide as a therapeutic agent.
The present invention is directed to the use of the pepti... |
|
|
Invention
|
Use of neuropeptide sf, alone or in combination with glp-2, as a therapeutic agent.
The present ... |
|
|
Invention
|
Therapeutic use of neuropeptide ei and acth 7-38 and compositions thereof.
The present invention... |
|
|
Invention
|
Therapeutic uses of gastrin- 1 and g- pen-grgdspca.
The present invention is directed to the use... |
|
|
Invention
|
Use of a laminin peptide as a therapeutic agent.
The present invention is directed to the use of... |
|
|
Invention
|
Use of leptin (22-56 ) as a therapeutic agent.
The present invention is directed to the use of t... |
|
|
Invention
|
Use of a defensin peptide as a therapeutic agent.
The present invention is directed to the use o... |
|
|
Invention
|
Therapeutic uses of intermedin 47 and 53 peptides.
The present invention is directed to the use ... |
|
|
Invention
|
Use of trp6-triptorelin and d-leu6-leuprolide as therapeutic agents.
The present invention is di... |
|
|
Invention
|
(d-leu7 ) -histrelin as a therapeutic agent.
The present invention is directed to the use of the... |
|
|
Invention
|
Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination wi... |
|
|
Invention
|
Use of band 3 protein (824-829) and/or melanocyte-stimulating hormone release-inhibiting factor a... |
|
|
Invention
|
Use of lvv-hemorphin-6 and optionally af12198 as therapeutic agent(s).
The present invention is ... |
|
|
Invention
|
Use of human neuropeptide as a therapeutic agent.
The present invention is directed to the use o... |
|
|
Invention
|
Use of bpp-b as a therapeutic agent.
The present invention is directed to the use of the peptide... |
|
|
Invention
|
Use of the peptide sfllr-oh and muramyl dipeptide as therapeutic agents.
The present invention i... |
|
|
Invention
|
Use of stresscopin-related peptide as a therapeutic agent.
The present invention is directed to ... |
|
|
Invention
|
Use of a galanin peptide as a therapeutic agent.
The present invention is directed to the use of... |
|
|
Invention
|
Use of acetyl- (ala10, 11)-rantes (1-14) and/or calcitonin as anti-angiogenic agents.
The presen... |
|
|
Invention
|
Use of calcitonin as anti-angiogenic agent.
The present invention is directed to the use of the ... |
|
|
Invention
|
Cgrp as a therapeutic agent.
The present invention is directed to the use of the peptide compoun... |
|
|
Invention
|
Use of the peptides maippkknqdk (cow kappa casein 106-116) and/or ygfqna (serorphin) as therapeut... |
